Development of single fluorophore biosensors for multiplex imaging of CAR T Signaling
Project Number1K01EB035649-01
Contact PI/Project LeaderLIU, LONGWEI
Awardee OrganizationUNIVERSITY OF SOUTHERN CALIFORNIA
Description
Abstract Text
Project Summary
The complexity and dynamics of protein kinases and epigenetic modifications in cellular processes necessitate
the development of precise biosensors for live imaging. This proposal aims to develop single-FP-based, high-
performance, ultrasensitive biosensors through directed evolution in mammalian cells. These biosensors will be
used in multiplexed imaging and dynamic visualization of signaling activities in situ, with a specific focus on
improving chimeric antigen receptor T cells (CAR-T) for cancer immunotherapy.
Addressing the limitations of CAR-T therapy, particularly T cell exhaustion in solid tumors, requires a
better understanding of the molecular mechanisms involved. Although kinases and epigenetic markers,
particularly H3K27me3, play key roles in T cell regulation, our understanding of their spatiotemporal dynamics
during cancer-immune interactions and through the course of CAR-T cell rejuvenation remains limited due to the
absence of appropriate investigative tools. Thus, parallel examination of these key regulators in cancer-immune
interacting environments should reveal new insights into the systematic behaviors and identify essential links for
therapeutic manipulation. My hypothesis is that 1) the reversal of CAR-T cell exhaustion involves a rejuvenation
of ZAP70 and Lck kinase’s function and a reprogramming of the H3K27me3, transitioning from an exhausted
state to a naïve T cell-like state; and 2) transient knockdown of exhaustion-related genes could prevent and
reverse exhaustion of CAR-T cells, which can be reflected by the kinase and epigenetics coordinated response
patterns.
Leveraging the combined expertise of my mentors, I have demonstrated the feasibility of engineering
single-FP biosensors for tyrosine kinases, directed evolution of single-FP biosensors in mammalian cells and
established a transient gene knockdown system that can be remotely controlled by focused ultrasound (FUS).
Building on these achievements, three distinct aims have been further proposed: Aim 1 focuses on engineering
novel single-FP prototype biosensors for monitoring tyrosine kinases or epigenetics in CAR-T cells of different
phenotypes during cancer cell engagement and establishing a multiplexed imaging platform. Aim 2 involves
developing ultrasensitive single-FP biosensors through directed evolution, high-throughput screening, and next-
generation sequencing. Aim 3 focuses on the application of these biosensors for multiplexed imaging and
manipulation of kinase-epigenome signaling in CAR-T cells using a FUS controllable gene knockdown system.
This biosensor engineering platform can potentially be extended to develop any other kinase and epigenetic
biosensors for live cell imaging. Similarly, the novel FUS-controllable gene knockdown system could be
generalized for broader manipulations of various cellular processes. Successful execution of this project could
revolutionize biosensor engineering and kinase imaging, profoundly impacting our understanding and treatment
of cancer and other diseases.
Public Health Relevance Statement
Project Narrative
The current proposal seeks to develop single-fluorophore-based, high-performance, ultrasensitive biosensors
for kinases and epigenetics. These biosensors will be used as functional multiparameter readouts to investigate
kinase-epigenome coordination to develop focused ultrasound controllable CAR-T Therapy. The success of this
project will revolutionize biosensor engineering and have a transformative impact on developing novel
controllable CAR-T cells for the treatment of cancer and other diseases.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
072933393
UEI
G88KLJR3KYT5
Project Start Date
01-April-2024
Project End Date
31-March-2028
Budget Start Date
01-April-2024
Budget End Date
31-March-2025
Project Funding Information for 2024
Total Funding
$151,548
Direct Costs
$140,322
Indirect Costs
$11,226
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$151,548
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1K01EB035649-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1K01EB035649-01
Patents
No Patents information available for 1K01EB035649-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1K01EB035649-01
Clinical Studies
No Clinical Studies information available for 1K01EB035649-01
News and More
Related News Releases
No news release information available for 1K01EB035649-01
History
No Historical information available for 1K01EB035649-01
Similar Projects
No Similar Projects information available for 1K01EB035649-01